<DOC>
	<DOC>NCT01123304</DOC>
	<brief_summary>This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.</brief_summary>
	<brief_title>Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed AJCC Stage IIIB, IIIC or IV melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules) Tumor accessible to intratumoral injections Cumulative tumor volume great enough to accept MORAb028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3 Are candidates for curative surgical excision or lymphadenectomy Prior nonsurgical treatment within 4 weeks Known central nervous system (CNS) tumor involvement or metastases Hypersensitivity to MORAb028</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>melanoma</keyword>
</DOC>